GLP-1s After Gallbladder Removal: Does the Warning Apply?

The question the label doesn't answer

The prescribing information has a warning about acute gallbladder disease. I would read that differently after gallbladder removal, but I would not assume the operation answers every question about abdominal symptoms or bile-duct problems. The important distinction is which outcomes were studied and whether those results apply after surgery.

I could not find a straight answer, so I went and read the actual studies. Here is what I found, including the part where it turns out nobody has really looked.

What the warning is actually made of

The warning is not vague. In the two Zepbound weight-reduction trials, cholelithiasis — gallstones — was reported in 1.1% of people on the drug against 1% on placebo, cholecystitis in 0.7% against 0.2%, and gallbladder removal itself in 0.2% against none on placebo. The label adds that these events were associated with the weight reduction¹.

The bigger picture comes from a meta-analysis in JAMA Internal Medicine that pooled 76 randomized trials and 103,371 people².

The association was larger in the weight-loss trials than in the diabetes and other trials. These are subgroup comparisons, not a way to calculate an individual person’s risk. The lower-dose estimate included both a possible reduction and a possible increase in risk; it does not demonstrate that the risk disappears².

What the evidence does not answer after surgery

Gallbladder inflammation and gallbladder removal are different from disease involving the wider biliary system. I would not collapse them into a claim that the whole warning becomes irrelevant after surgery. The combined outcome in the review includes gallbladder and biliary disease², so its overall estimate is not a surgery-specific risk estimate.

The meta-analysis included cholecystectomy as an outcome, but that alone does not prove every participant started with a gallbladder. More importantly for this question, the pooled results do not establish the risk specifically among women who had already had theirs removed. I would ask the prescriber how my surgical history changes the assessment rather than borrow the overall number as my own.

The honest limitation is that these figures do not establish either zero risk or a precise risk after gallbladder removal. I would keep the operation date, reason for surgery and any continuing digestive symptoms in the conversation. New symptoms still need assessment; they should not automatically be attributed to the medication or to the surgery.

What replaces it

This is the part I would actually want to know. Persistent or new symptoms after gallbladder removal are common enough to have their own name — post-cholecystectomy syndrome — and a 2025 review puts it at up to 47% of patients, with no consensus on how to diagnose or treat it even though it was described in 1947³.

One of its recognized forms is bile acid diarrhea. Without a gallbladder to store bile, it drips continuously into your gut, and for some people the result is urgent, frequent, loose stools. Losing the gallbladder is a well-documented secondary cause of it⁴.

Now put that next to a drug where diarrhea is one of the most commonly reported side effects. Two entirely separate causes, producing symptoms that feel identical. You will not be able to tell by feel which one you are having, and I think that is the practical thing to walk in knowing — not because it is alarming, but because "it's just the GLP-1" is an assumption worth checking rather than the obvious conclusion.

The part that genuinely surprised me

A review of bile acid diarrhea discusses bile acid sequestrants and research on liraglutide⁴. Liraglutide is a GLP-1 receptor agonist, but that does not establish that semaglutide or tirzepatide treats the same problem. I would ask about a specific diagnosis and treatment rather than infer a class-wide benefit.

I want to be careful with that, because it would be easy to read it as "my drug treats the problem." It is one drug in the class, and the review says plainly that whether this is a class effect is unclear⁴. Nobody should start or stay on a GLP-1 expecting it to fix bile acid diarrhea. But it does mean the relationship between these drugs and post-gallbladder guts is more interesting than a simple warning label, and worth raising with someone rather than assuming.

What I would ask

If I were starting one of these without a gallbladder, I would ask my prescriber three things. How the prescriber interprets the dose subgroup findings, which do not establish zero risk or a specific risk after surgery². Whether persistent diarrhea should be investigated as bile acid diarrhea rather than filed under drug side effects. And what the plan is if it does not settle, since bile acid diarrhea has actual treatments and waiting it out is not one of them.

None of this is medical advice — I am interpreting studies, not acting as your clinician. But I would rather walk in with the specific question than be told the general answer.